Literature DB >> 7702234

NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy.

P H Plotz1, L G Rider, I N Targoff, N Raben, T P O'Hanlon, F W Miller.   

Abstract

The myositis syndromes, the most common forms of which are polymyositis and dermatomyositis, are defined by idiopathic chronic inflammation in skeletal muscle. Although initially described more than a century ago, these diseases are so rare and heterogeneous that we have only a limited understanding of their causes and treatment. Recently, autoimmune responses to nuclear and cytoplasmic autoantigens that are unique to patients with myositis, the myositis-specific autoantibodies, have proved clinically useful in helping predict signs and symptoms of myositis, immunogenetics, responses to therapy, and prognosis. We summarize this new information on the variety and nature of these autoantibodies, their target epitopes, and their possible use in identifying causes, pathogenetic mechanisms, and better therapies for these increasingly recognized disorders.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7702234     DOI: 10.7326/0003-4819-122-9-199505010-00010

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  29 in total

1.  From black magic to science: understanding the rationale for the use of intravenous immunoglobulin to treat inflammatory myopathies.

Authors:  S Y Patel; D S Kumararatne
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

2.  Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.

Authors:  Sevim Barbasso Helmers; Maryam Dastmalchi; Helene Alexanderson; Inger Nennesmo; Mona Esbjörnsson; Björn Lindvall; Ingrid E Lundberg
Journal:  Ann Rheum Dis       Date:  2007-02-02       Impact factor: 19.103

Review 3.  [Inflammatory muscle diseases: dermatomyositis, polymyositis, and inclusion body myositis].

Authors:  E Genth
Journal:  Internist (Berl)       Date:  2005-11       Impact factor: 0.743

4.  Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series.

Authors:  Chaminda Basnayake; Kathy Cash; Peter Blumbergs; Vidya Limaye
Journal:  Clin Rheumatol       Date:  2013-12-13       Impact factor: 2.980

5.  Panniculitis as an Initial Presentation of Dermatomyositis: A Case Report.

Authors:  Anjal Bisht; Niraj Parajuli; Monasha Vaidya; Sumida Tiwari
Journal:  JNMA J Nepal Med Assoc       Date:  2020-03       Impact factor: 0.406

Review 6.  Recognition and management of myositis.

Authors:  P Cherin
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

7.  Comparative sequence analysis of ribonucleases HII, III, II PH and D.

Authors:  I S Mian
Journal:  Nucleic Acids Res       Date:  1997-08-15       Impact factor: 16.971

8.  Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia.

Authors:  Aryeh Fischer; Jeffrey J Swigris; Roland M du Bois; David A Lynch; Gregory P Downey; Gregory P Cosgrove; Stephen K Frankel; Evans R Fernandez-Perez; JoAnn Z Gillis; Kevin K Brown
Journal:  Respir Med       Date:  2009-06-03       Impact factor: 3.415

9.  [Update: dermatomyositis].

Authors:  B Volc-Platzer
Journal:  Hautarzt       Date:  2010-01       Impact factor: 0.751

10.  Long-term follow-up of nailfold videocapillaroscopic changes in dermatomyositis versus systemic sclerosis patients.

Authors:  C Pizzorni; M Cutolo; A Sulli; B Ruaro; A C Trombetta; G Ferrari; G Pesce; V Smith; S Paolino
Journal:  Clin Rheumatol       Date:  2018-07-13       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.